Description
Infections can be a significant problem for patients undergoing treatment for cancer. Research conducted by EORTC in Infectious Diseases aims to improve our understanding and management of such infectious complications.
Main Achievements
EORTC studies in infectious diseases dramatically changed the outcome for patients by significantly decreasing mortality due to septicemia.
They include:
- A landmark study comparing three antibiotic treatments for fever during neutropenia and presumed infection. The trial found an association with shock, temperature measure, and granulocyte and platelet counts at the onset of fever and gram-negative bacteremia.
- A large international trial which established voriconazole as the standard of treatment for proven and probable aspergillosis.
An EORTC study established definitions of invasive fungal disease in cancer patients, which has helped advance epidemiological, diagnostic and clinical research.
Our research has also helped improve the management of infections in cancer patients by better identifying risks and evaluating different treatment strategies.
Notable Publications
All publications on this research field-
2022
Empiric versus pre-emptive antifungal strategy in high-risk neutropenic patients on fluconazole prophylaxis: a randomized trial of the European organization for Research and Treatment of cancer (EORTC 65091)
-
2022
Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN)
-
2019
Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
-
2010
Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: An European Organisation for Research and Treatment of Cancer study
-
2009
An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in
